

Medicine Shortage Communication

02 July 2026

AZACTAM 1g and 2g (aztreonam powder for solution for injection): Supply shortage

Dear Healthcare Professionals,

Laboratoires DELBERT, is notifying healthcare professionals about a shortage of AZACTAM (aztreonam) 1g and 2g powder for solution for infusion.

This shortage affects all EU/EEA countries where the product is marketed.

The shortage is due to manufacturing issues of the new manufacturing site and not due to any safety, efficacy or quality concern with currently available supplies of Azactam.

Overview of situation

Supply shortages are affecting all markets. It is not clear when this shortage will end, however the company is working to restore normal supply as quickly as possible.

Mitigation measures

In order to mitigate the supply shortage, Laboratoires Delbert is engaging with the European Medicines Agency and National Competent Authorities to implement the following mitigation measures:

- Supply of additional batches to the EU/EEA from stock not originally intended for use in the EU/EEA
- Centralised EU/EEA stock management, including monitoring of inventory levels to support the allocation of supplies to countries based on demand and need.
- Implementation of controlled distribution measures in countries where it is feasible to do so

Healthcare professionals (HCPs) should consider the following mitigation measures:

- **Restrict use of Azactam to the following indications: <to be completed in consultation with National Competent Authorities>**
- **For all other indications, HCPs should consider alternative treatment approaches. <The following alternatives can be considered, depending on national prescribing guidelines and availability:**
- **to be completed in consultation with National Competent Authorities>**

For additional information consult your national competent authority website/national guidance.

Background on the shortage and the medicinal product

The shortage has been ongoing for a prolonged period and continues to affect the availability of Azactam throughout EU. While some countries are already experiencing shortages, others are expected to be impacted in the near future. It is not known when the shortage will be resolved.

Azactam is considered a critical medicinal product, particularly for the treatment of serious infections caused by susceptible Gram-negative bacteria in patients with limited therapeutic options. Importantly, there are currently no direct therapeutic alternatives available in the EU that can fully replace Azactam in all approved indications and patient populations.

For up-to-date information on the availability of Azactam and the alternatives in a particular EU/EEA country, consult the National Competent Authority.

Further information on these can be obtained by contacting the company contact point below, or the National Competent Authority.

Company contact point

<Contact point details for access to further information, including relevant website address(es), telephone numbers and a postal address>

FRANCE, BELGIUM, LUXEMBOURG, AUSTRIA, NORWAY, FINLAND, SWEDEN, Portugal, ROMANIA

affaires.pharmaceutiques@delbert.fr

<https://delbertpharma.com/fr/produit/azactam/>

+33 01 46 99 68 20

49 Rue Rouelle, 75015 Paris, France

SPAIN

galenicumderma@galenicum.com

+34 932 011 750

Carretera N-I ,Km 36, San Agustin de Guadalix, 28750 Madrid, Spain

Annexes (if applicable)

<Link/reference to other available relevant information, such as information on the website of a competent authority>

Communication Plan for Medicine Shortage Communication

MSC COMMUNICATION PLAN	
Medicinal product(s)/active substance(s)	AZACTAM 1 g powder for solution for injection AZACTAM 2 g powder for solution for injection
Marketing authorisation holder(s)	France (1g) / BELGIUM (1g&2g) / Luxembourg (1g&2g) / Portugal (1g) / AUSTRIA (1g&2g) / FINLAND (1g&2g) / NORWAY (2g)/ SWEDEN (1g&2g) / ROMANIA (1gr) : Laboratoires DELBERT (France) SPAIN (1g): GALENICUM DERMA (Spain)
Purpose of the communication	Inform of supply constraints and advise potential mitigation measures.
MSC recipients	Hospital pharmacists, anesthesiologists, intensivists, infectious disease specialists, pulmonologists, uro-nephrologists, gastroenterologists, visceral and orthopedic surgeons, hospital cardiologists. Relevant national Medical Societies. The target group should be further defined at national level, in agreement with the respective national competent authority.
Member States where the MSC will be distributed	France, Belgium, Luxembourg, Portugal, Austria, Finland, Norway, Sweden, Spain, Romania.
Timetable <i>[Delete steps which are not applicable]</i>	
MSC and communication plan (in English) agreed by SPOC WP	19.06.2026
MSC and communication plan (in English) agreed by MSSG	02.07.2026
Submission of translated MSCs to the national competent authorities for review	03.07.2026
Agreement of translations by national competent authorities	17.07.2026
Dissemination of MSC	17.07.2026